Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Cancers|July 24, 2021
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Cancer Science|September 27, 2023
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumabKazumasa Komura, Satoshi Tokushige, Mitsuaki Ishida, et al.
Frontiers in Oncology|March 16, 2026
Penile involvement associated with renal pelvic squamous cell carcinoma: a case report and mechanistic considerationsKotaro Masaki, Takuya Tsujino, Hiroyuki Okada, et al.
Urologic Oncology|July 31, 2024
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
Journal for Immunotherapy of Cancer|January 18, 2022
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancerKazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, et al.
International Journal of Clinical Oncology|December 10, 2024
Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitorsYasutaka Yamada, Kodai Sato, Shinichi Sakamoto, et al.
Prostate International|April 11, 2025
Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancerYasutaka Yamada, Shinichi Sakamoto, Takuya Tsujino, et al.
Molecular Cancer|November 19, 2023
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerKazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, et al.
Cancers|November 26, 2022
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus NivolumabYusuke Yano, Takaya Ohno, Kazumasa Komura, et al.
Cancer Medicine|September 14, 2023
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancerTakuya Tsujino, Satoshi Tokushige, Kazumasa Komura, et al.
Pageof 9